Sinphar Pharmaceutical Co.,Ltd. (TPE:1734)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
30.55
-0.05 (-0.16%)
Mar 10, 2026, 1:35 PM CST
2.16%
Market Cap 5.82B
Revenue (ttm) 3.35B
Net Income (ttm) 345.57M
Shares Out 190.20M
EPS (ttm) 1.81
PE Ratio 16.91
Forward PE n/a
Dividend 0.95 (3.09%)
Ex-Dividend Date Jul 11, 2025
Volume 340,202
Average Volume 237,872
Open 30.35
Previous Close 30.60
Day's Range 30.35 - 30.75
52-Week Range 25.95 - 32.60
Beta 0.14
RSI 46.98
Earnings Date Mar 20, 2026

About Sinphar Pharmaceutical

Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, including antineoplastic, ophthalmic, ENT, oral, respiratory system, dermatology, analgesic and NSAIDs, metabolic and nutrient, gastrointestinal, and oth... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1977
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 1734
Full Company Profile

Financial Performance

In 2024, Sinphar Pharmaceutical's revenue was 3.15 billion, an increase of 6.33% compared to the previous year's 2.96 billion. Earnings were 304.71 million, a decrease of -18.78%.

Financial Statements

News

There is no news available yet.